The Rich Get Richer
This article was originally published in Start Up
Executive SummaryCash is king and the more you've got, the more investors are willing to give. At least that's the message in medical devices. Start-Up examined recent private offerings of public medical device companies to see if there was a relationship between the cash a company had and the valuation new private investors were willing to afford the company.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.